Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 10.79% is 16% below its 5-year average of 12.84%, around the middle of its 5-year range (5.31%–23.14%).
As of the fiscal period ended Wednesday, December 31, 2025. 11.07% above its 12-month average of 9.71%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
10.79%
RETURN ON EQUITY (ROE) AVG TTM
9.71%
RETURN ON EQUITY (ROE) AVG 3Y
9.35%
RETURN ON EQUITY (ROE) AVG 5Y
12.84%
RETURN ON EQUITY (ROE) AVG 10Y
12.85%
RETURN ON EQUITY (ROE) AVG 15Y
15.46%
RETURN ON EQUITY (ROE) AVG 20Y
17.65%
CURRENT VS TTM AVG
+11.07%
CURRENT VS 3Y AVG
+15.37%
CURRENT VS 5Y AVG
-15.97%
CURRENT VS 10Y AVG
-16.05%
CURRENT VS 15Y AVG
-30.22%
CURRENT VS 20Y AVG
-38.87%
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-0.92%
vs the sector median at left
Labcorp Holdings Inc.
Market Cap
$25.77B
Return on Equity (ROE)
10.79%
TTM Avg
9.71%
3Y Avg
9.35%
5Y Avg
12.84%
Market Cap
$25.96B
Return on Equity (ROE)
25.41%
TTM Avg
12.92%
3Y Avg
11.29%
5Y Avg
9.83%
Market Cap
$26.04B
Return on Equity (ROE)
18.49%
TTM Avg
13.34%
3Y Avg
14.07%
5Y Avg
18.07%
Market Cap
$25.02B
Return on Equity (ROE)
2.94%
TTM Avg
29.98%
3Y Avg
64.02%
5Y Avg
111.55%
Market Cap
$23.72B
Return on Equity (ROE)
18.89%
TTM Avg
16.95%
3Y Avg
19.08%
5Y Avg
20.56%
Market Cap
$28.06B
Return on Equity (ROE)
-3677.41%
TTM Avg
-2178.82%
3Y Avg
-341.14%
5Y Avg
-117.12%
Market Cap
$23.38B
Return on Equity (ROE)
-6.79%
TTM Avg
-4.55%
3Y Avg
10.63%
5Y Avg
21.70%
Market Cap
$28.88B
Return on Equity (ROE)
31.47%
TTM Avg
28.93%
3Y Avg
25.01%
5Y Avg
22.95%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Labcorp Holdings Inc. (LH) | $25.77B | 10.79% | 9.71% | 9.35% | 12.84% |
| Incyte Corporation (INCY)vs › | $25.96B | 25.41% | 12.92% | 11.29% | 9.83% |
| Quest Diagnostics Incorporated (DGX)vs › | $26.04B | 18.49% | 13.34% | 14.07% | 18.07% |
| Waters Corporation (WAT)vs › | $25.02B | 2.94% | 29.98% | 64.02% | 111.55% |
| West Pharmaceutical Services, Inc. (WST)vs › | $23.72B | 18.89% | 16.95% | 19.08% | 20.56% |
| Mettler-Toledo International Inc. (MTD)vs › | $28.06B | -3677.41% | -2178.82% | -341.14% | -117.12% |
| BioNTech SE (BNTX)vs › | $23.38B | -6.79% | -4.55% | 10.63% | 21.70% |
| DexCom, Inc. (DXCM)vs › | $28.88B | 31.47% | 28.93% | 25.01% | 22.95% |
| STERIS plc (STE)vs › | $22.45B | 10.89% | 10.12% | 7.00% | 7.00% |
| GE HealthCare Technologies Inc. (GEHC)vs › | $29.16B | 14.11% | 21.84% | 21.53% | 32.27% |
ROE
10.8%
ROA
4.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 10.17% |
| 2024-12-31 | 9.26% |
| 2023-12-31 | 5.31% |
| 2022-12-31 | 12.67% |
| 2021-12-31 | 23.14% |
| 2020-12-31 | 16.49% |
| 2019-12-31 | 10.89% |
| 2018-12-31 | 12.68% |
| 2017-12-31 | 18.64% |
| 2016-12-31 | 13.30% |
| 2015-12-31 | 8.84% |
| 2014-12-31 | 18.12% |
| 2013-12-31 | 23.03% |
| 2012-12-31 | 21.46% |
| 2011-12-31 | 20.76% |
| 2010-12-31 | 22.63% |
| 2009-12-31 | 25.80% |
| 2008-12-31 | 27.51% |
| 2007-12-31 | 27.64% |
| 2006-12-31 | 21.83% |
| 2005-12-31 | 20.48% |
| 2004-12-31 | 18.16% |
| 2003-12-31 | 16.93% |
| 2002-12-31 | 15.80% |
| 2001-12-31 | 16.54% |
| 2000-12-31 | 12.78% |
| 1999-12-31 | 8.91% |
| 1998-12-31 | 10.10% |
| 1997-12-31 | -16.97% |
| 1996-12-31 | -59.47% |
